NCT05127395已完成不适用
Impact of Dosing Weight on Clinical Outcomes in Obese Patients Receiving Acyclovir for HSV Encephalitis (ID-OPRAH)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- In-hospital mortality
研究概览
简要总结
Multicenter retrospective chart review of patients admitted to any of the six study centers (SSM Health - St. Clare, St. Mary's, Saint Louis University Hospital, St. Anthony's, St. Mary's Madison, Rush University Medical Center, or Methodist Dallas Medical Center) between January 1, 2013 and December 31, 2019 will be conducted. All study centers utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
详细描述
- Obese - WHO definition: Body Mass Index > 30 kg/m2
- Ideal Body Weight (IBW) (male) - 50.0 kg + 2.3 kg x (patient height in inches, above 60 inches)
- Ideal Body Weight (female) - 45.5 kg + 2.3 kg x (patient height inches, above 60 inches)
- Adjusted Body Weight - IBW + [0.4 x (ABW - IBW)]
- HSV encephalitis - PCR positive for HSV-1 or HSV-2 in CSF during index admission
- Baseline Serum Creatinine (S Cr) - The SCr value obtained before the start of acyclovir therapy on which the dose of acyclovir should be based upon
- Acute Kidney Injury (AKI) - per RIFLE criteria and while receiving acyclovir: SCr doubles or urine output < 0.5 mL/kg/hour for 12 hours
- End-stage renal disease (ESRD) on admission - mention of a diagnosis of ESRD in electronic medical records prior to receipt of acyclovir
- Guideline-approved, weight-based doses - within 10% of 10 mg/kg dose (to account for rounding due to vial size)
- Adequate hydration - IV fluid order (other than KVO [keep vein open]) within 24 hours before acyclovir start AND either IV fluid order (other than KVO) for majority of acyclovir course or IV fluid + oral diet for majority of acyclovir course
- Appropriately renally dose-adjusted doses - Frequency of acyclovir matches package insert recommendations based on creatinine clearance at baseline
- Interacting medications - Mycophenolate, probenecid, zidovudine, tenofovir, valproic acid, phenytoin
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients Admitted to a SSM Health - St. Clare (STL), St. Mary's (STL), Saint Louis University Hospital (STL), St. Anthony's (OKC), St. Mary's Madison (WIS), Rush University Medical Center (RUMC), or Methodist Dallas Medical Center
- •> 18 years old
- •Positive cerebrospinal fluid (CSF) PCR for HSV-1 or HSV-2
- •BMI > 30 kg/m2
- •Received guideline-approved, weight-based doses of IV acyclovir for HSV encephalitis for at least 72 hours during the index admission
- •Received appropriately renal dose-adjusted doses of IV acyclovir per package insert recommendations
排除标准
- •More than one dosing weight strategy utilized for > 24 hours for IV acyclovir dosing during the index admission
- •Patients transferred to the hospital already on IV acyclovir for HSV encephalitis
- •ESRD on admission
- •Concomitant pathogen causing meningitis or encephalitis
- •Oral acyclovir used for treatment
结局指标
主要结局
In-hospital mortality
时间窗: Over 1 month
Will assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric SurgeryObesity, MorbidBariatric Surgery CandidateNCT02310178University Hospital, Montpellier750
已完成
不适用
Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT RegistryAcute Renal Failure (ARF)Acute Kidney Injury (AKI)Fluid Overload in Dialysis PatientsNCT06633029Vantive Health LLC59
已完成
不适用
Pulsed Radiofrequency of Lateral Femoral Cutaneous NerveMeralgia ParestheticaNCT06187883Mersin Training and Research Hospital30
已完成
2 期
A Dose-defining Study of OPC-41061 in Treatment of Hepatic EdemaCirrhosisNCT00479336Otsuka Pharmaceutical Co., Ltd.104
已完成
4 期
Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency PatientsHypertension EmergencyEnd-organ DamageNCT01872039Astellas Pharma China, Inc.163